Strength in Numbers: Identifying Neoantigen Targets for Cancer Immunotherapy | Zendy

Rigel J. Kishton | Zendy; Rachel C. Lynn | Zendy; Nicholas P. Restifo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Strength in Numbers: Identifying Neoantigen Targets for Cancer Immunotherapy

Author(s) -

Rigel J. Kishton,

Rachel C. Lynn,

Nicholas P. Restifo

Publication year - 2020

Publication title -

cell

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 26.304

H-Index - 776

eISSN - 1097-4172

pISSN - 0092-8674

DOI - 10.1016/j.cell.2020.10.011

Subject(s) - biology , immunotherapy , cancer immunotherapy , cancer research , antigen , somatic cell , cancer , adoptive cell transfer , t cell , chimeric antigen receptor , immune system , computational biology , immunology , gene , genetics

Targeting cancer neoantigens generated by tumor-exclusive somatic mutations is an attractive yet challenging strategy for the robust and specific elimination of tumor cells by cellular immunotherapy. In this issue of Cell, Wells et al. describe a consortium-based approach to optimize bioinformatics pipelines to sensitively and accurately predict immunogenic neoantigens from next-generation sequencing data.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research